Morning, Marco. Munich wrapped yesterday, and the closing day handed you one trial that will change what you do with a syncope admission and one that quietly closes a chapter in device cardiology. Both are honest about what they didn't show, which is the theme of the whole congress. Below that: the Gulf woke up on the last day of August, Iran and the US traded strikes over the weekend, and the statin question you've been asked at three bedsides this month now has real data on both sides — that's the debate.
A · Top Stories
Trial · Syncope
ASPIRED: a patch monitor at the ED door doubled arrhythmia detection — and did nothing for recurrent syncope
Presented in the final Hot Line block in Munich yesterday and published simultaneously in the New England Journal of Medicine. UK multicentre, open-label: 2,233 adults (mean age 58.3, 48% women) whose syncope remained unexplained after ED evaluation, randomized to an immediate 14-day ambulatory ECG patch or their hospital's usual pathway. Primary endpoint was neutral — mean self-reported syncope episodes at one year 1.37 vs. 1.58, incidence rate ratio 0.89 (95% CI 0.68–1.18, p=0.43). But detection of clinically significant arrhythmia more than doubled, 22% vs. 9%, and one-year mortality was 1.5% vs. 2.9%. Congress coverage.
Why it matters to you: Unexplained syncope in a 79-year-old is one of your most common 2 a.m. admissions, and the reason you admit is almost never "to stop the fainting" — it's to catch the pause, the block, or the VT before it kills them. ASPIRED is aimed exactly at that. Read the endpoints in the right order: the trial failed to reduce how often people faint, which was never a plausible mechanism for a monitor, and it succeeded at the thing you actually want, which is finding the rhythm. Treat the mortality signal with care — a secondary outcome in an open-label trial, plausible but not the headline the abstract earned.
Suggested action: Find out whether your ED can place a 14-day patch at discharge, or whether the only route is an outpatient cardiology referral six weeks out. If the patch is available, ASPIRED is the argument for using it as a discharge tool rather than an admission substitute — and for some of your low-risk observation holds, that changes the disposition conversation entirely.
Trial · Devices
DANISH-CRT: aiming the LV lead at the latest-activated site didn't beat aiming it wherever it fits
Also presented yesterday in Munich, published simultaneously in The Lancet. Patients undergoing cardiac resynchronization therapy were randomized to targeted left ventricular lead placement at the site of latest electrical activation vs. standard placement. At a median 45.8 months, death or first unplanned heart-failure hospitalization occurred in 27.9% with targeting vs. 25.5% with standard — hazard ratio 1.10 (95% CI 0.86–1.39, p=0.45). Secondary endpoints told the same story: no difference in reverse remodeling, quality of life, functional status or exercise capacity, and nothing emerged in subgroups. ESC press release.
Why it matters to you: Indirectly, but it matters. The observational data behind targeting looked strong for a decade, and a large randomized trial just found nothing — a useful reminder next time you're handed a "well-established" association as a reason to escalate. Practically, it means the CRT non-responder who keeps bouncing back to your service isn't going to be rescued by a better lead position, and the question worth asking on those admissions moves back to medical therapy optimization, AV nodal conduction, and whether the patient is actually pacing enough.
Talking point: Pairs well with the ASPIRED result for a journal-club or group-meeting slot — two closing-day trials where the technology worked and the outcome didn't follow.
Operational · Florida
The Gulf woke up on the last day of August, and the Caribbean is the one to watch for the weekend
The NHC designated Potential Tropical Cyclone Five in the northern Gulf yesterday, with watches and warnings up for the upper Texas coast and southwest Louisiana. It's a rain event, not a wind event — flash flooding is the stated primary hazard, with impacts Tuesday into early Wednesday, and the track takes it away from Florida. Closer to home: the remnants of Dolly are pushing tropical moisture across the state and raising rain chances through midweek, and forecasters are flagging a separate tropical disturbance moving into the Caribbean that could matter to Florida by Labor Day weekend. Local 10 · CBS Miami.
Why it matters to you: Nothing is threatening Lee County today. But the season has been quiet — four named storms and no hurricanes through August, against a below-normal seasonal forecast — and quiet Augusts have a way of making September staffing plans feel theoretical. September 10 is the climatological peak. You work nights; you are the person who gets called when a storm shift needs covering with twelve hours' notice.
Suggested action: Ten minutes this week: confirm you know your hospital's current activation tier and who is on your ride-out roster, before something in the Caribbean has a name and everyone is asking at once.
B · The Debate
Should a healthy 75-year-old with no heart disease start a statin?
Why it's live right now: STAREE, the first large primary-prevention statin trial in adults over 70, reported in Munich on Saturday and published in NEJM: 9,971 Australians (mean age 74.7, 52% women), atorvastatin 40 mg vs. placebo, median 5.9 years. Major adverse cardiovascular events fell 30% (6.0% vs. 8.3%, p<0.001) — but disability-free survival, the co-primary composite of death, dementia or persistent physical disability, was unchanged. Three days earlier at the same congress, the SAGA/SITE data suggested older patients on statins for primary prevention can safely stop. The USPSTF has said for years that evidence is insufficient over 76; roughly 40% of STAREE was 75 or older.
The case for starting
François Mach, MD — Geneva University Hospital, ESC trial discussant; via TCTMD, Aug 29, 2026
Age has functioned as an evidence vacuum rather than a contraindication, and that vacuum is now filled. STAREE shows a 30% relative reduction in MI, stroke and revascularization in exactly the population guidelines have refused to address, with benefits holding in the over-75 subgroup and serious adverse events balanced between arms. Lead author Sophia Zoungas notes about half of participants already had musculoskeletal complaints at baseline and the drug added little to them — 32.0% vs. 29.4%. Mach's position is that guidelines "have to be adapted accordingly": a fit 75-year-old with a 15-year runway is being denied a cheap, well-characterized therapy on the basis of a birthday rather than a risk estimate.
The case for not reflexively starting
Abdulla A. Damluji, MD, PhD — Cleveland Clinic, chair of the ACC Geriatric Cardiology Leadership Council; via TCTMD, Aug 29, 2026
The trial reduced events without preserving independence, and for an older adult those are not the same purchase. Damluji's reading: "The curves separate after roughly 2 years, so a patient unlikely to survive 5 more years, or who is already frail and carrying substantial polypharmacy, may gain little." Eighty percent of deaths in STAREE were non-cardiovascular, which is why a large MACE reduction didn't move disability-free survival. The harms are small but real and land on people already juggling pills — hepatobiliary events 3.3% vs. 0.9%, new diabetes-related events 4.0% vs. 2.7%, 7.2% stopping for an adverse event. And the SAGA/SITE results from the same week suggest stopping is a defensible option too.
Where it might land: PREVENTABLE — 20,000 patients, same 40 mg atorvastatin, powered for dementia and disability — is the trial that settles whether event reduction in this age group buys anything beyond events. Guideline committees on both continents will be under pressure to write something before it reads out.